Protocol Study Chair Information for Patients and Families Information for Health Professionals NCI Trial ID
PBTC-029B:
A Phase I and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Jason Fangusaro, MD
Ann and Robert H. Lurie Hospital of Chicago
225 East Chicago Avenue, Box 30
Chicago, IL. 60611
Phone: (312) 227-4846
Email: jfangusaro@luriechildrens.org
Summary for Patients and Families Abstract for Health Professionals NCT01089101
PBTC-042:
Phase I study of CDK 4-6 inhibitor PD- 0332991 (palbociclib; IBRANCE) in children with recurrent, progressive or refractory central nervous system tumors
David Van Mater, MD, PhD
Duke University Medical Center
Durham, North Carolina 27710
Phone: (919) 684-3401
Fax: (919) 681-7950
Email: david.vanmater@duke.edu
Summary for Patients and Families Abstract for Health Professionals NCT02255461
PBTC-043:
A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors
Jason Fangusaro, MD
Ann and Robert H. Lurie Hospital of Chicago
Chicago, Illinois 60611
Phone: 312-227-4846
Fax: 312-227-9756
Email: jfangusaro@luriechildrens.org
Summary for Patients and Families Abstract for Health Professionals NCT02415153
PBTC-045:
A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs
Eugene Hwang, MD
Children’s National Medical Center
111 Michigan Ave, NS
Washington, DC 20010
Telephone: 202-476-5046
Fax: 202-476-4304
Email: ehwang@childrensnational.org
Summary for Patients and Families Abstract for Health Professionals NCT02359565
PBTC-047:
A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Michelle Monje, MD PhD
Stanford University and Lucile Packard Children's Hospital
750 Welch Road, Suite 317
Palo Alto, CA 94304
Phone: (650) 721-5750
Fax: (650) 723-7299
Email: mmonje@stanford.edu
Summary for Patients and Families Abstract for Health Professionals NCT02717455
PBTC-048:
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Stewart Goldman, MD
Ann & Robert Lurie Children’s Hospital of Chicago
Neuro-oncology Box 30
255 East Chicago Ave.
Chicago, Il 60611
Phone: (312) 227-4844
Fax: (312) 227-9756
Email: sgoldman@luriechildrens.org
Summary for Patients and Families Abstract for Health Professionals NCT03033992
PBTC-050:
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors
Mariko DeWire-Schottmiller, M.D.
Cincinnati Children’s Hospital Medical Center
3333 Burnet Avenue, MLC 7015
Cincinnati, OH 45229
Phone: (513) 803-1126
Fax: (513) 636-3549
Email: mariko.dewire@cchmc.org
Summary for Patients and Families Abstract for Health Professionals NCT03387020
PBTC-051:
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Ira Dunkel, MD
Memorial Sloan Kettering Cancer Center
Department of Pediatrics
Howard 1102
New York, NY 10065
Phone: (212) 639-2153
Fax: (212) 717-3239
Email: dunkeli@mskcc.org
Summary for Patients and Families Abstract for Health Professionals NCT03389802
Protocol Study Chair Information for Health Professionals PubMed ID
PBTC-001:
Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals PMC3529096
PBTC-002:
A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors
Mark W. Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals PMC2775441
PBTC-003:
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors
Mark W. Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals PMID17634493
PBTC-004:
Phase I Study of Intrathecal SpartajectTM-Busulfan in Children with Neoplastic Meningitis
Sri Gururangan, MRCP (UK)
University of Florida
Gainesville, FL
Phone: (352) 294-8347
Email: gururangan@ufl.edu
Abstract for Health Professionals PMID16533779
PBTC-005:
Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-3604
Email: amar.gajjar@stjude.org
Abstract for Health Professionals PMID18006772
PBTC-006:
A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas
Ian F. Pollack, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA.
Phone: (412) 692-5881
Email: ian.pollack@chp.edu
Abstract for Health Professionals PMC1871662
PBTC-007:
A Phase I/II Trial of ZD1839 (IressaTM) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II limited to Brain Stem Tumors
J. Russell Geyer, MD
Seattle Children's Hospital
Seattle, WA.
Phone: (206) 987-6664
Email: russ.geyer@seattlechildrens.org
Abstract for Health Professionals PMC2988095
PBTC-009:
Phase I Trial of GLIADEL® and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas
Ian F. Pollack, MD
Children's Hospital of Pittsburgh
Pittsburgh, PA.
Phone: (412) 692-5881
Email: ian.pollack@chp.edu
Abstract for Health Professionals  
PBTC-010:
A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors
Maryam Fouladi, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Phone: (513) 803-0721
Email: maryam.fouladi@cchmc.org
Abstract for Health Professionals PMID17019740
PBTC-011C:
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma
Anuradha Banerjee, MD, MPH
University of California, San Francisco
San Francisco, CA.
Phone: (415) 353-2966
Email: Banerjee@neurosurg.ucsf.edu
Abstract for Health Professionals  
PBTC-012:
Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors
Tobey MacDonald, MD
Children's Healthcare of Atlanta
Atlanta, GA
Phone: (404) 727-1447
Email: tobey.macdonald@emory.edu
Abstract for Health Professionals PMID18281665
PBTC-013:
A Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-a and a Mutated Form of the Pseudomonas Exotoxin Termed PE38 (TP-38) in Pediatric Patients with Recurrent or Progressive Supratentorial High Grade Gliomas
Roger Packer, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 884-2120
Email: rpacker@cnmc.org
Abstract for Health Professionals  
PBTC-014:
Phase I/II Trial of Zarnestra and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
Daphne Haas-Kogan, MD
Harvard Medical School
Boston, MA
Phone: (617) 632-2291
Email: dhaas-kogan@lroc.harvard.edu
Abstract for Health Professionals PMC2563056
PBTC-015:
A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors
Kathy Warren, MD
National Cancer Institute
Pediatric-Oncology Branch
Bethesda, MD.
Phone: (301) 402-6298
Email: warrenk@mail.nih.gov
Abstract for Health Professionals PMC3518022
PBTC-016:
A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma
Maryam Fouladi, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Phone: (513) 803-0721
Email: maryam.fouladi@cchmc.org
Abstract for Health Professionals PMC2953974
PBTC-017:
Phase I Study of CLORETAZINE ™ (VNP4010M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors
Sri Gururangan, MRCP (UK)
University of Florida
Gainesville, FL
Phone: (352) 294-8347
Email: gururangan@ufl.edu
Abstract for Health Professionals PMID18281546
PBTC-018:
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors
Kathy Warren, MD
National Cancer Institute
Pediatric-Oncology Branch
Bethesda, MD.
Phone: (301) 402-6298
Email: warrenk@mail.nih.gov
Abstract for Health Professionals PMC3056466
PBTC-019:
A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals PMC3573253
PBTC-020:
A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumor
Mark Kieran, MD, PhD
Dana-Farber Cancer Institute
Boston, MA.
Phone: (617) 632-4907
Email: mark_kieran@dfci.harvard.edu
Abstract for Health Professionals PMC4561207
PBTC-021:
A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals PMC3661085
PBTC-022:
Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Sri Gururangan, MRCP (UK)
University of Florida
Gainesville, FL
Phone: (352) 294-8347
Email: gururangan@ufl.edu
Abstract for Health Professionals PMC2903337
PBTC-023:
Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors
Susan Blaney, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4586
Email: sblaney@txccc.org
Abstract for Health Professionals PMC4288513
PBTC-024:
A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
Maryam Fouladi, MD
Cincinnati Children's Hospital Medical Center,
Cincinnati, OH.
Phone: (513) 636-4266
Email: maryam.fouladi@cchmc.org
Abstract for Health Professionals PMC3179253
PBTC-025:
A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals PMC3856244
PBTC-025B:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
St Jude Children's Research Hospital
Memphis, TN.
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals PMC4534527
PBTC-026:
A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
Sarah Leary, MD
Seattle Children's Hospital
Seattle, WA.
Phone: (206) 987-2106
Email: sarah.leary@seattlechildrens.org
Abstract for Health Professionals  
PBTC-027:
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors
Jack Su, MD
Texas Children's Research Hospital
Houston, TX.
Phone: (832) 822-4306
Email: jmsu@txccc.org
Abstract for Health Professionals PMC4232081
PBTC-030:
A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas
Lindsay Kilburn, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 476-2800
Email: LKilburn@childrensnational.org
Abstract for Health Professionals  
PBTC-031:
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors
Roger Packer, MD
Children's National Medical Center
Washington, DC.
Phone: (202) 476-5973
Email: rpacker@cnmc.org
Abstract for Health Professionals PMC4330963
PBTC-032:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
St. Jude Children's Research Hospital
Memphis, TN
Phone: (901) 595-4599
Email: amar.gajjar@stjude.org
Abstract for Health Professionals PMC4534527
PBTC-033:
A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
Patricia A. Baxter, MD
Texas Children's Cancer Center
Houston, TX.
Phone: (832) 824-4681
Email: pabaxter@txch.org
Abstract for Health Professionals  
PBTC-037:
A phase I study of intratumoral/peritumoral herpes simplex virus-1 mutant HSV1716 in patients with refractory or recurrent high grade gliomas (HGG)
Mariko DeWire, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH.
Phone: (513) 636-4266
Email: mariko.dewire@cchmc.org
Abstract for Health Professionals  
PBTC-039:
A Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma
Stewart Goldman, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Phone: (312) 227-4844
Email: sgoldman@luriechildrens.org
Abstract for Health Professionals NCT01964300
PBTC-041:
A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors
Stewart Goldman, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Phone: (312) 227-4844
Email: sgoldman@luriechildrens.org
Abstract for Health Professionals PMC4999001